Log In Get Started
Press Releases May 19, 2026 08:00 AM

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

BioCardia to engage in virtual fireside chat at Alliance Global Partners Healthcare Showcase

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
BCDA

BioCardia, Inc., a Nasdaq-listed company specializing in cellular therapeutics for cardiovascular and pulmonary diseases, announced its upcoming participation in a virtual fireside chat during the Alliance Global Partners Healthcare Company Showcase. The event, scheduled for May 20, 2026, will provide insights into BioCardia's therapeutic platforms and advancements.

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
BCDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BioCardia is focused on cellular and cell-derived therapies for heart and lung diseases.
  • The company utilizes proprietary platforms including CardiAMP® and CardiALLO™ for treatment development.
  • Participation in the A.G.P. Healthcare Showcase offers exposure to investors and stakeholders in the healthcare sector.

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.

Fireside Chat Details:

  • Time: 11:40 AM ET
  • Date: Wednesday, May 20, 2026

Investors can register for the conference and view the fireside chat here.

About BioCardia®

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: www.BioCardia.com.


Risks

  • The fireside chat itself does not present new product or financial disclosures, limiting immediate impact.
  • Market interest in biotech companies can be sensitive to clinical trial results, regulatory developments, and commercialization prospects not addressed here.
  • Broader healthcare market volatility and competition in cell therapy sectors may affect BioCardia's outlook.

More from Press Releases

RMG ML Sports Holdings Announces the Pricing of $200 Million Initial Public Offering Jun 9, 2026 BlockchAIn Announces Closing of $55 Million Public Offering of Common Stock Jun 9, 2026 Maui Land & Pineapple Company, Inc. Appoints a Chief Investment Officer Jun 9, 2026 Applied Digital Announces Pricing of $1.59 Billion of Senior Secured Notes to fund the Fourth Building at Polaris Forge 1 Jun 9, 2026 Einride, a Global Leader in Autonomous and Electric Freight, Completes Business Combination and Will Begin Trading on Nasdaq Stock Market Jun 9, 2026